References
- BarryMJFowlerFLO’LearyMPThe American Urological Association Symptom Index for benign prostatic hyperplasiaJ Urol19921485154915571279218
- BarryMJWillifordWOChangWBenign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?J Urol19951545177017747563343
- AndersonJBRoehrbornCGSchalkenJAEmbertonMThe progression of benign prostatic hyperplasia: examining the evidence and determining the riskEur Urol200139439039911306876
- MadersbacherSMarszalekMLacknerJBergerPSchatzlGThe long-term outcome of medical therapy for BPHEur Urol20075161522153317416456
- MarksLSRoehrbornCGAndrioleGLPrevention of benign prostatic hyperplasia diseaseJ Urol20061764 Pt 11299130616952616
- DjavanBWaldertMGhawidelCMarbergerMBenign prostatic hyperplasia progression and its impact on treatmentCurr Opin Urol2004141455015091050
- RoehrbornCGDefinition of at-risk patients: baseline variablesBJU Int200697Suppl 2711 discussion 21–2216507046
- McConnellJDRoehrbornCGBautistaOMThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med2003349252387239814681504
- OelkeMBachmannADescazeaudMEAU Guidelines on Conservative Treatment of Non-neurogenic Male LUTSArnhem, The NetherlandsEuropean Association of Urology2010 Available from: http://www.uroweb.org/gls/pdf/BPH%202010.pdfAccessed June 24, 2011
- ClarkRVHermannDJCunninghamGRWilsonTHMorrillBBHobbsSMarked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitorJ Clin Endocrinol Metab2004892179218415126539
- KirbyRSRoehrbornCBoylePEfficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trialUrology200361111912612559281
- LeporHWillifordWOBarryMJThe efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study GroupN Engl J Med199633585335398684407
- LeporHNonoperative management of benign prostatic hyperplasiaJ Urol1989141128312892470925
- McConnellJDBruskewitzRWalshPThe effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasiaN Engl J Med19983385575639475762
- KaplanSAMcConnellJDRoehrbornCGCombination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greaterJ Urol2006175121722 discussion 220–22116406915
- DebruyneFBarkinJvan ErpsPEfficacy and safety of long- term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasiaEur Urol200446448849515363566
- AbramsPSchulmanCCVaageSTamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). The European Tamsulosin Study GroupBr J Urol19957633253367551841
- RoehrbornCBoylePGouldALWaldstreicherJSerum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasiaUrology199953358158910096388
- RoehrbornCGSiamiPBarkinJThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol201057112313119825505
- SiamiPRoehrbornCGBarkinJCombination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study designContemp Clin Trials200728677077917761460
- NaslundMEaddyMTHogueSLKruepEJShahMBImpact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgeryCurr Med Res Opin200925112663266919757985
- RoehrbornCSiamiPBarkinJThe effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT studyJ Urol20091792616621 discussion 62118082216
- BarkinJRoehrbornCSiamiPEffect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trialBJU Int2008103791992619239460
- MontorsiFHenkelTGeboersAEffect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT studyInt J Clin Pract20106481042105120487046
- BarkinJGuimarãesMJacobiGPushkarDTaylorSvan Vierssen TripOBAlpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasterideEur Urol200344446146614499682